Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate in Relapsed/Refractory Aggressive NHL and Hodgkin's Disease
NCT00052442Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Aug 2002
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pralatrexate in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) (5 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate at 3 weeks. Started Aug 2002; status: completed.
02
Drugs
pralatrexate
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00052442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052442.